Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study

BACKGROUND: The evidence of combined therapies of multi-target agents in first-line treatment of advanced non-small cell lung cancer (NSCLC) was limited. This study aimed to evaluate the safety and efficacy of anlotinib combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Tianqing, Zhang, Wei, Zhang, Bo, Zhong, Runbo, Zhang, Xueyan, Gu, Aiqin, Shi, Chunlei, Wang, Huimin, Xiong, Liwen, Lu, Jun, Qian, Jianlin, Zhang, Yanwei, Dong, Yu, Teng, Jiajun, Gao, Zhiqiang, Wang, Weimin, Shen, Yinchen, Nie, Wei, Lim, Jeong Uk, Mehta, Hiren J., Neal, Joel W., Lou, Yuqing, Xu, Jianlin, Zhong, Hua, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359953/
https://www.ncbi.nlm.nih.gov/pubmed/35958322
http://dx.doi.org/10.21037/tlcr-22-438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359953/
https://www.ncbi.nlm.nih.gov/pubmed/35958322
http://dx.doi.org/10.21037/tlcr-22-438

Ejemplares similares